Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/3/2024
- Wall St ends sharply higher, US jobs data strengthens case for rate cuts
- U.S. adds fewer jobs than anticipated in April
- Apple shares rise more than 5% premarket after Q2 results top downbeat estimates
- Amgen (AMGN) stock soars on positive obesity drug update, analyst raises PT
- Oil settles down on US jobs data, steepest weekly loss in 3 months
- Midday movers: Apple, Amgen and Block rise; Cloudflare and Expedia fall
- After-hours movers: Apple, Block, Coinbase, Booking and more
- Midday movers: Carvana and Qualcomm rise; DoorDash, Fastly, Zillow fall
- After-hours movers: Qualcomm, Carvana rise; DoorDash, Etsy, Fastly fall
- Midday movers: Amazon, Pfizer, Pinterest rise; AMD, Starbucks, CVS Health fall
Johnson & Johnson (JNJ) Reports a Beat-and-Raise 3Q, Analyst Positive
October 19, 2021 7:53 AM EDTJohnson & Johnson (NYSE: JNJ) reported better-than-expected 3Q results today and left its vaccine guidance unchanged.
The company reported Q3 EPS of $2.60 to top the analyst estimate of $2.36. However, revenue for the quarter came in at $23.3 billion to miss the consensus estimate of $23.74 billion. The company left its COVID-19 vaccine sales target unchanged at $2.5... More
